Abstract
To the Editor.— Duvoisin et al 1 reported that administration of pyridoxine may cancel the therapeutic and the side effects of levodopa. This was confirmed in several centers, including our own. 2 Consequently, industry produced and marketed a pyridoxine-free preparation (Larobec) which covers needs for vitamins in patients receiving levodopa. While continuing our experiments with the peripheral metabolic inhibitor D, L-alpha-methyl dopahydrazine or MK 485, 3 we noted that diurnal variations in performance could be controlled with orally administered combinations of inhibitor and levodopa. Such combinations have also diminished the striking postprandial reemergence of symptoms otherwise experienced by some of our patients. 2,3 We were thus encouraged to test whether the inhibitor blocked the adverse effects of administered pyridoxine. Pyridoxine (up to 100 mg three times each day) was given orally to seven patients for at least one week while they were in a metabolic ward and were receiving combinations
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
